Soleno Therapeutics Inc Financials
This page shows Soleno Therapeutics Inc (SLNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Soleno Therapeutics Inc has an operating margin of 4.9%, meaning the company retains $5 of operating profit per $100 of revenue. This results in a moderate score of 33/100, indicating healthy but not exceptional operating efficiency.
Soleno Therapeutics Inc carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.80, Soleno Therapeutics Inc holds $5.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Soleno Therapeutics Inc converts 24.5% of revenue into free cash flow ($46.7M). This strong cash generation earns a score of 86/100.
Soleno Therapeutics Inc generates a 4.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 21/100. This is up from -71.7% the prior year.
Soleno Therapeutics Inc scores 10.70, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.0B) relative to total liabilities ($113.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Soleno Therapeutics Inc passes 5 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Soleno Therapeutics Inc generates $2.24 in operating cash flow ($46.8M OCF vs $20.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Soleno Therapeutics Inc earns $1.7 in operating income for every $1 of interest expense ($9.4M vs $5.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Soleno Therapeutics Inc generated $190.4M in revenue in fiscal year 2025.
Soleno Therapeutics Inc's EBITDA was $11.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 106.2% from the prior year.
Soleno Therapeutics Inc reported $20.9M in net income in fiscal year 2025. This represents an increase of 111.9% from the prior year.
Soleno Therapeutics Inc earned $0.39 per diluted share (EPS) in fiscal year 2025. This represents an increase of 108.9% from the prior year.
Cash & Balance Sheet
Soleno Therapeutics Inc generated $46.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 167.4% from the prior year.
Soleno Therapeutics Inc held $70.1M in cash against $49.9M in long-term debt as of fiscal year 2025.
Soleno Therapeutics Inc had 52M shares outstanding in fiscal year 2025. This represents an increase of 14.4% from the prior year.
Margins & Returns
Soleno Therapeutics Inc's gross margin was 98.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Soleno Therapeutics Inc's operating margin was 4.9% in fiscal year 2025, reflecting core business profitability.
Soleno Therapeutics Inc's net profit margin was 11.0% in fiscal year 2025, showing the share of revenue converted to profit.
Soleno Therapeutics Inc's ROE was 4.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 76.4 percentage points from the prior year.
Capital Allocation
Soleno Therapeutics Inc invested $40.6M in research and development in fiscal year 2025. This represents a decrease of 48.3% from the prior year.
Soleno Therapeutics Inc spent $100.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Soleno Therapeutics Inc invested $73K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.5% from the prior year.
SLNO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $66.0M+102.2% | $32.7M | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $1.1M+63.9% | $696K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $64.9M+103.0% | $32.0M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $8.4M-8.1% | $9.1M-32.3% | $13.5M | N/A | $30.1M+144.2% | $12.3M-15.5% | $14.6M |
| SG&A Expenses | N/A | $33.8M+19.5% | $28.2M-3.5% | $29.3M | N/A | $49.2M+351.8% | $10.9M+28.5% | $8.5M |
| Operating Income | N/A | $22.1M+438.8% | -$6.5M+85.7% | -$45.7M | N/A | -$80.2M-222.6% | -$24.9M-5.9% | -$23.5M |
| Interest Expense | N/A | $1.4M+1.0% | $1.4M+1.1% | $1.4M | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | $26.0M+652.5% | -$4.7M+89.2% | -$43.8M | N/A | -$76.6M-250.6% | -$21.9M-2.1% | -$21.4M |
| EPS (Diluted) | N/A | $0.47+622.2% | $-0.09+90.5% | $-0.95 | N/A | $-1.83-221.1% | $-0.57+3.4% | $-0.59 |
SLNO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $563.8M-6.0% | $599.9M+80.5% | $332.3M+4.5% | $318.1M-3.9% | $331.0M+11.5% | $296.7M-2.4% | $304.1M+80.1% | $168.8M |
| Current Assets | $355.8M-33.5% | $534.9M+68.8% | $316.8M+2.5% | $308.9M+5.1% | $293.9M+13.8% | $258.2M-3.5% | $267.5M+76.9% | $151.2M |
| Cash & Equivalents | $70.1M-71.6% | $246.7M+222.4% | $76.5M-5.9% | $81.3M-7.5% | $87.9M+81.6% | $48.4M-15.1% | $57.0M+33.1% | $42.8M |
| Inventory | $15.0M+125.1% | $6.7M+183.4% | $2.4M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $28.2M+10.6% | $25.5M+3.6% | $24.6M | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $113.7M+8.2% | $105.1M+14.0% | $92.2M+7.4% | $85.8M0.0% | $85.9M+168.3% | $32.0M+36.9% | $23.4M-8.2% | $25.5M |
| Current Liabilities | $61.4M+84.5% | $33.3M+58.8% | $20.9M+33.1% | $15.7M-16.1% | $18.7M+25.3% | $15.0M+63.5% | $9.2M-32.0% | $13.5M |
| Long-Term Debt | $49.9M0.0% | $49.9M0.0% | $49.8M0.0% | $49.8M0.0% | $49.8M | N/A | N/A | N/A |
| Total Equity | $450.1M-9.0% | $494.8M+106.0% | $240.1M+3.4% | $232.3M-5.2% | $245.1M-7.4% | $264.7M-5.7% | $280.8M+95.8% | $143.4M |
| Retained Earnings | -$431.4M+9.1% | -$474.7M+5.2% | -$500.7M-0.9% | -$496.0M-9.7% | -$452.3M-14.1% | -$396.3M-24.0% | -$319.7M-7.3% | -$297.8M |
SLNO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $48.7M+12.1% | $43.5M+444.7% | -$12.6M+61.5% | -$32.8M-36.5% | -$24.0M-60.7% | -$14.9M+15.4% | -$17.7M-40.9% | -$12.5M |
| Capital Expenditures | $58K+5700.0% | $1K-88.9% | $9K+80.0% | $5K-37.5% | $8K-95.8% | $191K+2287.5% | $8K-27.3% | $11K |
| Free Cash Flow | $48.6M+12.0% | $43.5M+444.4% | -$12.6M+61.5% | -$32.8M-36.5% | -$24.0M-58.8% | -$15.1M+14.4% | -$17.7M-40.8% | -$12.5M |
| Investing Cash Flow | -$125.4M-37.1% | -$91.4M-1055.3% | -$7.9M-134.5% | $22.9M+256.0% | $6.4M+59.5% | $4.0M+103.3% | -$120.9M-4.9% | -$115.2M |
| Financing Cash Flow | -$99.9M-145.8% | $218.2M+1290.5% | $15.7M+387.5% | $3.2M-94.4% | $57.1M+2408.3% | $2.3M-98.5% | $152.7M+16184.5% | $938K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SLNO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 98.3%+0.4pp | 97.9% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | 33.5%+53.5pp | -20.0% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | 39.4%+53.8pp | -14.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | 5.3%+7.2pp | -2.0%+16.9pp | -18.9% | N/A | -28.9%-21.2pp | -7.8%+7.1pp | -14.9% |
| Return on Assets | N/A | 4.3%+5.8pp | -1.4%+12.3pp | -13.8% | N/A | -25.8%-18.6pp | -7.2%+5.5pp | -12.7% |
| Current Ratio | 5.80-10.3 | 16.08+1.0 | 15.13-4.5 | 19.64+4.0 | 15.68-1.6 | 17.26-12.0 | 29.24+18.0 | 11.23 |
| Debt-to-Equity | 0.110.0 | 0.10-0.1 | 0.210.0 | 0.21+0.0 | 0.20+0.1 | 0.12+0.0 | 0.08-0.1 | 0.18 |
| FCF Margin | N/A | 65.8%+104.5pp | -38.6% | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Soleno Therapeutics Inc's annual revenue?
Soleno Therapeutics Inc (SLNO) reported $190.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Soleno Therapeutics Inc profitable?
Yes, Soleno Therapeutics Inc (SLNO) reported a net income of $20.9M in fiscal year 2025, with a net profit margin of 11.0%.
What is Soleno Therapeutics Inc's EBITDA?
Soleno Therapeutics Inc (SLNO) had EBITDA of $11.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Soleno Therapeutics Inc have?
As of fiscal year 2025, Soleno Therapeutics Inc (SLNO) had $70.1M in cash and equivalents against $49.9M in long-term debt.
What is Soleno Therapeutics Inc's gross margin?
Soleno Therapeutics Inc (SLNO) had a gross margin of 98.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Soleno Therapeutics Inc's operating margin?
Soleno Therapeutics Inc (SLNO) had an operating margin of 4.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Soleno Therapeutics Inc's net profit margin?
Soleno Therapeutics Inc (SLNO) had a net profit margin of 11.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Soleno Therapeutics Inc's return on equity (ROE)?
Soleno Therapeutics Inc (SLNO) has a return on equity of 4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Soleno Therapeutics Inc's free cash flow?
Soleno Therapeutics Inc (SLNO) generated $46.7M in free cash flow during fiscal year 2025. This represents a 167.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Soleno Therapeutics Inc's operating cash flow?
Soleno Therapeutics Inc (SLNO) generated $46.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Soleno Therapeutics Inc's total assets?
Soleno Therapeutics Inc (SLNO) had $563.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Soleno Therapeutics Inc's capital expenditures?
Soleno Therapeutics Inc (SLNO) invested $73K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Soleno Therapeutics Inc spend on research and development?
Soleno Therapeutics Inc (SLNO) invested $40.6M in research and development during fiscal year 2025.
What is Soleno Therapeutics Inc's current ratio?
Soleno Therapeutics Inc (SLNO) had a current ratio of 5.80 as of fiscal year 2025, which is generally considered healthy.
What is Soleno Therapeutics Inc's debt-to-equity ratio?
Soleno Therapeutics Inc (SLNO) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Soleno Therapeutics Inc's return on assets (ROA)?
Soleno Therapeutics Inc (SLNO) had a return on assets of 3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Soleno Therapeutics Inc's Altman Z-Score?
Soleno Therapeutics Inc (SLNO) has an Altman Z-Score of 10.70, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Soleno Therapeutics Inc's Piotroski F-Score?
Soleno Therapeutics Inc (SLNO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Soleno Therapeutics Inc's earnings high quality?
Soleno Therapeutics Inc (SLNO) has an earnings quality ratio of 2.24x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Soleno Therapeutics Inc cover its interest payments?
Soleno Therapeutics Inc (SLNO) has an interest coverage ratio of 1.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Soleno Therapeutics Inc?
Soleno Therapeutics Inc (SLNO) scores 68 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.